Overview

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Status:
Not yet recruiting

Trial end date:
2026-12-28

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial (called the FLOTILLA study) is to provide continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants in prior encorafenib and/or binimetinib studies may participate the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they have not enrolled in a prior study of encorafenib or binimetinib, or if they have stopped receiving the study treatment in a prior study. Participants in the FLOTILLA study will receive encorafenib and/or binimetinib at the same dose and frequency as in their prior study, for up to about 5 years.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Cetuximab